Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000231
Collaborator
University of Vermont (Other)
0
1
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate buprenorphine and behavioral treatment with and without contingent payment on compliance with pro-social activities. In addition, we will examine whether blind naltrexone dosing is effective in indicating naltrexone consumption.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Buprenorphine Detoxification With Two Types of Treatment. BBD IV
Study Start Date
:
Feb 1, 1992
Outcome Measures
Primary Outcome Measures
- Drug use []
- Retention []
- Weeks abstinent []
- Weeks continuous abstinence []
- Overall treatment outcome []
- Naltrexone consumption []
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Treatment Research Center | Burlington | Vermont | United States | 05401 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
- University of Vermont
Investigators
- Principal Investigator: Warren Bickel, Ph.D., University of Vermont
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00000231
Other Study ID Numbers:
- NIDA-06969-13
- R01-06969-13
First Posted:
Sep 21, 1999
Last Update Posted:
Aug 17, 2005
Last Verified:
Mar 1, 1994